Roslin Institute joins collective research alliance
The alliance hopes to provide 'a coherent, authoritative voice'.
The Roslin Institute has become part of an alliance of more than 40 institutions dedicated to the advancement of science and research.
The National Research Organisation (NRO) Group, supported by science minister Patrick Vallance, will seek to benefit people, communities, the economy, the environment and national resilience.
The collaboration was devised amid as part of plans to strengthen the United Kingdom’s research landscape. It was suggested it would benefit from stronger strategic alignment, clearer governance and greater visibility into the abilities of national research organisations.
The alliance will now work to provide ‘a coherent, authoritative voice on science, research policy and long-term investment’.
Among the priorities set out by the alliance is the goal of delivering a measurable impact against government priorities, aligning research projects with national needs and securing sustainable investment. It will also hope to foster innovation and skills, as well as strengthening the UK’s global scientific leadership.
Lord Patrick Vallance, Science Minister, said: “The UK's strength in science and innovation depends on collaboration across our research ecosystem. National research organisations play a vital role in generating the knowledge, infrastructure and expertise that support economic growth, improve lives and help address the major challenges facing the country.
“I welcome the launch of the National Research Organisations Group and look forward to working with its members to maximise the impact of UK science and research.”
Prof John Hammond, director of the Roslin Institute, added: “Roslin offers national capability to achieve sustainable agriculture, control diseases and enhance health through pioneering animal bioscience. We look forward to working with the NRO group to amplify this capability and deliver benefits for the UK in support of Government strategic priorities.”
Image © Shutterstock.com/Gorodenkoff
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
